Rabbit Anti-Human LYL1 (a.a. 1-280) Polyclonal antibody

Name: Rabbit Anti-Human LYL1 (a.a. 1-280) Polyclonal antibody
SKU: DPABH-27918
Rating: 5 (1 reviews)

Rabbit Anti-Human LYL1 (a.a. 1-280) Polyclonal antibody for IP, ELISA

Write a review

COA

SDS

Datasheet

Key features and details

Target: Human LYL1
Host: Rabbit
Application: IP, ELISA
Species Reactivity: Human

Summary

Specifications

Antibody Isotype

IgG

Species Reactivity

Human

Immunogen

Recombinant human LYL1 protein; Source: E. coli derived, PET28a; Tag: 6*His; Domain: 1-280 aa of BC002796

Conjugate

Unconjugated

Applications

Application Notes

IP: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

General Notes

This product (Catalog No. DPABH-27918) is a rabbit-derived polyclonal antibody raised against human LYL1, targeting the amino acid region 1–280 of the protein. It has been affinity purified by Protein A. Lymphoblastic leukemia1 (LYL1) is a proto-oncogenic transcription factor found upregulated in patients with T-cell acute lymphoblastic leukemia (T-cell ALL). LYL1 has an important role in hematopoietic stem cell biology, normal hematopoiesis and leukemia. It is expressed throughout the hematopoietic lineages with the exception of T-cells. LYL1 shows two bands in the WB detection, where the upper band is the phosphorylated form and the lower band is the non-phosphorylated form (PMID: 10023675, PMID: 20844761).
DPABH-27918 is suitable for use in IP (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate) application.
DPABH-27918 is supplied as a liquid formulation in PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.

Target

Alternative Names

Protein lyl-1; Lymphoblastic leukemia-derived sequence 1; Class A basic helix-loop-helix protein 18; bHLHa18

Entrez Gene ID

4066

UniProt ID

P12980

Citations

Have you cited DPABH-27918 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Constitutive Expression of MEF2C, LYL1, or LMO2 in CD34(+) HSCs Blocks the in Vitro Differentiation before the T-Cell Commitment Point and Could be Oncogenic in Early T-Cell Progenitor ALL

BLOOD

Authors: Cante-Barrett, Kirsten; Mendes, Rui D.; Smits, Wilco K.; Pieters, Rob; Meijerink, Jules P. P.

Abstract

Single-cell transcriptomics reveals a new dynamical function of transcription factors during embryonic hematopoiesis

ELIFE

Authors: Bergiers, Isabelle; Andrews, Tallulah; Bolukbasi, Ozge Vergel; Buness, Andreas; Janosz, Ewa; Lopez-Anguita, Natalia; Ganter, Kerstin; Kosim, Kinga; Celen, Cemre; Percin, Gulce Itir; Collier, Paul; Baying, Bianka; Benes, Vladimir; Hemberg, Martin; Lancrin, Christophe

Abstract

Recent advances in single-cell transcriptomics techniques have opened the door to the study of gene regulatory networks (GRNs) at the single-cell level. Here, we studied the GRNs controlling the emergence of hematopoietic stem and progenitor cells from mouse embryonic endothelium using a combination of single-cell transcriptome assays. We found that a heptad of transcription factors (Runx1, Gata2, Tal1, Fli1, Lyl1, Erg and Lmo2) is specifically co-expressed in an intermediate population expressing both endothelial and hematopoietic markers. Within the heptad, we identified two sets of factors of opposing functions: one (Erg/Fli1) promoting the endothelial cell fate, the other (Runx1/Gata2) promoting the hematopoietic fate. Surprisingly, our data suggest that even though Fli1 initially supports the endothelial cell fate, it acquires a pro-hematopoietic role when co-expressed with Runx1. This work demonstrates the power of single-cell RNA-sequencing for characterizing complex transcription factor dynamics.